Context Therapeutics stockholders approve reverse stock split and ratify auditor at 2025 annual meeting

Context Therapeutics Inc.

66,716,026 shares (74.37% of outstanding) present at June 12, 2025 annual meeting.
Ratified CohnReznick LLP as auditor for FY2025 with 66,649,293 votes for, 20,039 against.
Approved reverse stock split at ratio from 1:5 to 1:50, as determined by Board; 65,141,783 for, 1,540,542 against.
No broker non-votes reported; both proposals were routine matters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.